See more : Masraf Al Rayan (Q.P.S.C.) (MARK.QA) Income Statement Analysis – Financial Results
Complete financial analysis of Celldex Therapeutics, Inc. (CLDX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Celldex Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Frequentis AG (FQT.DE) Income Statement Analysis – Financial Results
- Capstone Infrastructure Corporation (CPOIF) Income Statement Analysis – Financial Results
- Earth Science Tech, Inc. (ETST) Income Statement Analysis – Financial Results
- Agri-tech (India) Limited (AGRITECH.NS) Income Statement Analysis – Financial Results
- Parvati Sweetners and Power Lt (PARVATI.BO) Income Statement Analysis – Financial Results
Celldex Therapeutics, Inc. (CLDX)
About Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.88M | 2.36M | 4.65M | 7.42M | 3.57M | 9.54M | 12.74M | 6.79M | 5.48M | 3.59M | 4.11M | 11.20M | 9.27M | 46.79M | 15.18M | 7.46M | 5.10M | 4.93M | 3.09M | 6.86M | 4.63M | 6.70M | 3.35M | 763.20K | 1.48M | 2.20M | 1.20M | 1.10M | 4.00M | 7.00M | 9.00M | 6.60M | 10.20M | 10.90M | 7.80M | 4.60M | 2.20M | 100.00K |
| Cost of Revenue | 3.01M | 1.40M | 3.07M | 42.53M | 42.67M | 66.45M | 96.17M | 102.03M | 4.01M | 101.88M | 2.33M | 10.78M | 9.12M | 12.08M | 8.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 41.00K | 36.80K | -689.30K | -712.80K | -400.00K | -300.00K | -100.00K | 1.20M | 1.20M | 1.50M | 600.00K | 1.10M | 800.00K | 800.00K | 300.00K | -100.00K | 0.00 |
| Gross Profit | 3.88M | 957.00K | 1.58M | -35.12M | -39.10M | -56.91M | -83.43M | -95.24M | 1.47M | -98.30M | 1.78M | 427.00K | 146.00K | 34.72M | 6.78M | 7.46M | 5.10M | 4.93M | 3.09M | 6.86M | 4.63M | 6.66M | 3.31M | 1.45M | 2.20M | 2.60M | 1.50M | 1.20M | 2.80M | 5.80M | 7.50M | 6.00M | 9.10M | 10.10M | 7.00M | 4.30M | 2.30M | 100.00K |
| Gross Profit Ratio | 56.30% | 40.60% | 34.04% | -473.39% | -1,094.29% | -596.68% | -654.70% | -1,403.48% | 26.81% | -2,741.08% | 43.23% | 3.81% | 1.58% | 74.19% | 44.68% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 99.39% | 98.90% | 190.32% | 148.05% | 118.18% | 125.00% | 109.09% | 70.00% | 82.86% | 83.33% | 90.91% | 89.22% | 92.66% | 89.74% | 93.48% | 104.55% | 100.00% |
| Research & Development | 118.01M | 82.26M | 53.31M | 42.53M | 42.67M | 66.45M | 96.17M | 102.73M | 100.17M | 104.38M | 67.40M | 47.40M | 32.44M | 27.65M | 26.17M | 26.35M | 18.50M | 18.07M | 14.06M | 13.87M | 10.02M | 14.71M | 21.58M | 10.77M | 7.87M | 5.70M | 5.30M | 6.00M | 8.00M | 8.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 30.91M | 27.20M | 20.49M | 14.46M | 15.43M | 19.27M | 25.00M | 35.98M | 33.84M | 20.62M | 14.81M | 10.02M | 9.24M | 10.43M | 17.12M | 14.75B | 8.50B | 0.00 | 6.89B | 0.00 | 0.00 | 0.00 | 4.91M | 4.81M | 4.28M | 3.80M | 3.50M | 6.50M | 5.90M | 5.80M | 16.00M | 0.00 | 12.90M | 11.50M | 8.30M | 6.10M | 3.70M | 1.90M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -14.73B | -8.49B | 0.00 | -6.89B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 30.91M | 27.20M | 20.49M | 14.46M | 15.43M | 19.27M | 25.00M | 35.98M | 33.84M | 20.62M | 14.81M | 10.02M | 9.24M | 10.43M | 17.12M | 14.75M | 8.50M | 8.24M | 6.89M | 5.57M | 5.35M | 5.59M | 4.91M | 4.81M | 4.28M | 3.80M | 3.50M | 6.50M | 5.90M | 5.80M | 16.00M | 10.10M | 12.90M | 11.50M | 8.30M | 6.10M | 3.70M | 1.90M |
| Other Expenses | 12.50M | 90.34M | 55.38M | 54.02M | 42.71M | 224.00K | 896.00K | 997.00K | 1.01M | 1.01M | 1.01M | 1.09M | 1.91M | 3.14M | 345.00K | 361.01K | 960.21K | 995.11K | 995.11K | 995.10K | 995.10K | 795.10K | 1.38M | 1.31M | 1.99M | 1.00M | 400.00K | 500.00K | 700.00K | 800.00K | 900.00K | 600.00K | 600.00K | 500.00K | 300.00K | 200.00K | 200.00K | 100.00K |
| Operating Expenses | 161.43M | 109.45M | 73.80M | 56.99M | 58.10M | 85.94M | 122.07M | 139.70M | 135.02M | 126.02M | 83.22M | 58.50M | 43.60M | 41.17M | 43.63M | 41.46M | 27.96M | 27.30M | 21.95M | 20.44M | 16.37M | 21.10M | 27.87M | 16.89M | 14.14M | 10.50M | 9.20M | 13.00M | 14.60M | 15.30M | 16.90M | 10.70M | 13.50M | 12.00M | 8.60M | 6.30M | 3.90M | 2.00M |
| Cost & Expenses | 161.43M | 109.45M | 73.80M | 56.99M | 58.10M | 85.94M | 122.07M | 139.70M | 135.02M | 126.02M | 85.55M | 69.28M | 52.71M | 53.25M | 52.03M | 41.46M | 27.96M | 27.30M | 21.95M | 20.44M | 16.37M | 21.14M | 27.91M | 16.20M | 13.43M | 10.10M | 8.90M | 12.90M | 15.80M | 16.50M | 18.40M | 11.30M | 14.60M | 12.80M | 9.40M | 6.60M | 3.80M | 2.00M |
| Interest Income | 13.11M | 0.00 | 505.00K | 2.41M | 4.15M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 530.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 151.09M | 15.97M | 0.00 | 0.00 | 0.00 | 927.00K | 1.58M | 1.80M | 1.34M | 452.00K | 156.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.01M | 1.40M | 3.07M | 2.00M | 4.86M | 3.80M | 5.31M | 4.09M | 1.01M | 1.01M | 2.95M | 1.09M | 1.91M | 3.14M | 3.53M | 2.54M | 2.69M | 2.10M | 2.13M | 1.72M | 1.53M | 1.62M | 2.26M | 1.31M | 1.99M | 1.00M | 400.00K | 500.00K | 700.00K | 800.00K | 900.00K | 600.00K | 600.00K | 500.00K | 300.00K | 200.00K | 200.00K | 100.00K |
| EBITDA | -139.03M | -104.20M | -66.08M | -45.64M | -49.67M | -72.60M | -104.02M | -124.44M | -125.53M | -116.53M | -77.68M | -54.41M | -38.84M | 4.67M | -33.07M | -44.96M | -19.07M | -18.16M | -16.50M | -11.82M | -10.21M | -12.81M | -22.30M | -14.13M | -9.96M | -6.95M | -7.31M | -11.30M | -11.10M | -8.70M | -8.50M | -4.10M | -5.90M | -3.80M | -1.40M | -1.30M | -1.80M | -1.40M |
| EBITDA Ratio | -2,019.96% | -4,321.89% | -1,452.55% | -514.92% | -1,628.10% | -6.66% | -753.60% | -2,008.62% | -2,388.18% | -3,385.86% | -1,909.44% | -508.72% | -453.12% | -7.08% | -219.49% | -240.92% | -416.70% | -453.96% | -566.77% | -178.53% | -225.49% | -200.04% | -720.66% | -995.26% | -713.91% | 1,677.27% | -150.00% | -1,118.18% | -367.50% | -94.29% | -107.78% | -74.24% | -46.08% | -20.18% | -25.64% | -56.52% | -104.55% | -1,900.00% |
| Operating Income | -154.54M | -115.23M | -71.24M | -63.35M | -55.03M | -156.44M | -121.53M | -132.92M | -129.54M | -122.43M | -81.44M | -58.08M | -43.40M | -6.46M | -36.85M | -48.76M | -22.85M | -22.37M | -18.87M | -13.58M | -11.73M | -14.43M | -24.56M | -15.44M | -11.94M | -7.90M | -7.70M | -11.80M | -11.80M | -9.50M | -9.40M | -4.70M | -4.40M | -1.90M | -1.60M | -2.00M | -1.60M | -1.90M |
| Operating Income Ratio | -2,245.27% | -4,889.01% | -1,531.78% | -854.06% | -1,540.19% | -1,640.13% | -953.68% | -1,958.68% | -2,363.89% | -3,414.11% | -1,981.08% | -518.45% | -468.42% | -13.79% | -242.75% | -653.96% | -447.88% | -453.60% | -610.85% | -198.03% | -253.28% | -215.25% | -734.07% | -2,023.17% | -805.14% | -359.09% | -641.67% | -1,072.73% | -295.00% | -135.71% | -104.44% | -71.21% | -43.14% | -17.43% | -20.51% | -43.48% | -72.73% | -1,900.00% |
| Total Other Income/Expenses | 13.11M | 2.91M | 505.00K | 2.41M | 4.15M | 4.49M | 4.21M | 4.39M | 2.34M | 4.35M | -108.00K | -1.05M | -1.35M | 3.92M | -4.20M | 1.26M | -6.25M | 2.11M | 768.45K | 378.60K | 239.80K | 602.70K | 1.81M | -6.53M | 635.20K | 49.60K | -5.50M | 1.00M | 3.60M | -2.10M | 1.20M | 800.00K | 3.00M | 3.30M | 1.00M | 800.00K | 1.30M | 100.00K |
| Income Before Tax | -141.43M | -112.33M | -70.74M | -60.95M | -50.88M | -151.95M | -117.31M | -128.53M | -127.20M | -118.08M | -81.55M | -59.12M | -44.80M | -2.53M | -37.05M | -62.26M | -21.76M | -20.25M | -18.10M | -13.20M | -11.49M | -13.83M | -22.75M | -21.98M | -11.31M | -7.90M | -13.20M | -10.80M | -8.20M | -11.60M | -8.20M | -3.90M | -3.50M | -1.10M | -900.00K | -1.20M | -700.00K | -1.80M |
| Income Before Tax Ratio | -2,054.76% | -4,765.59% | -1,520.92% | -821.61% | -1,423.96% | -1,593.09% | -920.61% | -1,894.05% | -2,321.11% | -3,292.81% | -1,983.70% | -527.79% | -483.53% | -5.41% | -244.10% | -835.04% | -426.40% | -410.74% | -585.96% | -192.51% | -248.10% | -206.26% | -680.03% | -2,879.32% | -762.33% | -359.09% | -1,100.00% | -981.82% | -205.00% | -165.71% | -91.11% | -59.09% | -34.31% | -10.09% | -11.54% | -26.09% | -31.82% | -1,800.00% |
| Income Tax Expense | 0.00 | 10.46M | -227.00K | -1.17M | -506.00K | -765.00K | -24.28M | -8.77M | -2.34M | -4.35M | -819.00K | -530.00K | -446.00K | -5.31M | -529.00K | 27.00M | -120.00K | 120.00K | -1.54M | -757.20K | 695.70K | -1.21M | -3.62M | 13.07M | -1.27M | 87.70M | 10.90M | -2.00M | -7.10M | 4.20M | -2.80M | -1.90M | -1.90M | -1.70M | -1.20M | -1.60M | -1.70M | -300.00K |
| Net Income | -141.43M | -122.78M | -70.51M | -59.78M | -50.37M | -151.18M | -93.03M | -128.53M | -127.20M | -118.08M | -81.55M | -59.12M | -44.80M | -2.53M | -36.53M | -47.50M | -21.64M | -20.37M | -18.10M | -13.20M | -12.67M | -13.83M | -22.75M | -21.98M | -11.31M | -51.80M | -13.10M | -10.80M | -8.30M | -11.60M | -7.80M | -3.60M | -3.40M | -1.00M | -1.10M | -1.20M | -800.00K | -1.70M |
| Net Income Ratio | -2,054.76% | -5,209.29% | -1,516.04% | -805.88% | -1,409.80% | -1,585.07% | -730.06% | -1,894.05% | -2,321.11% | -3,292.81% | -1,983.70% | -527.79% | -483.53% | -5.41% | -240.61% | -637.12% | -424.05% | -413.17% | -585.96% | -192.51% | -273.47% | -206.26% | -680.03% | -2,879.32% | -762.33% | -2,354.55% | -1,091.67% | -981.82% | -207.50% | -165.71% | -86.67% | -54.55% | -33.33% | -9.17% | -14.10% | -26.09% | -36.36% | -1,700.00% |
| EPS | -2.92 | -2.62 | -1.64 | -2.02 | -3.47 | -14.48 | -10.86 | -18.99 | -19.66 | -19.81 | -15.33 | -15.37 | -17.01 | -1.19 | -27.64 | -50.12 | -468.75 | -49.41 | -43.93 | -32.57 | -36.48 | -41.17 | -70.63 | -75.43 | -46.18 | -281.04 | -89.06 | -89.61 | -85.46 | -122.55 | -82.48 | -48.26 | -57.95 | -18.89 | -23.80 | -26.22 | -17.49 | -37.21 |
| EPS Diluted | -2.92 | -2.62 | -1.64 | -2.02 | -3.47 | -14.48 | -10.86 | -18.99 | -19.66 | -19.81 | -15.33 | -15.37 | -17.01 | -1.19 | -27.64 | -50.12 | -468.75 | -49.41 | -43.93 | -32.57 | -36.48 | -41.17 | -70.63 | -75.43 | -46.18 | -281.04 | -89.06 | -89.61 | -85.46 | -122.55 | -82.48 | -48.26 | -57.95 | -18.89 | -23.80 | -26.22 | -17.49 | -37.21 |
| Weighted Avg Shares Out | 48.45M | 46.89M | 42.87M | 29.64M | 14.51M | 10.44M | 8.57M | 6.77M | 6.47M | 5.96M | 5.32M | 3.85M | 2.63M | 2.12M | 1.32M | 947.80K | 46.16K | 412.31K | 411.91K | 405.36K | 347.29K | 335.90K | 322.12K | 291.32K | 244.87K | 184.32K | 147.10K | 120.52K | 97.12K | 94.66K | 94.57K | 74.59K | 58.67K | 52.93K | 46.22K | 45.77K | 45.75K | 45.69K |
| Weighted Avg Shares Out (Dil) | 48.45M | 46.89M | 42.87M | 29.64M | 14.51M | 10.44M | 8.57M | 6.77M | 6.47M | 5.96M | 5.32M | 3.85M | 2.63M | 2.12M | 1.32M | 947.80K | 46.16K | 412.31K | 411.91K | 405.36K | 347.29K | 335.90K | 322.12K | 291.32K | 244.87K | 184.32K | 147.10K | 120.52K | 97.12K | 94.66K | 94.57K | 74.59K | 58.67K | 52.93K | 46.22K | 45.77K | 45.75K | 45.69K |
Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases
HAMPTON, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in the Company's Phase 1a study of CDX-622 in healthy volunteers. CDX-622 is a bispecific antibody that targets two...
Celldex Therapeutics to Present at Upcoming Investor Conferences
HAMPTON, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences:
Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $0.81 per share a year ago.
Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
HAMPTON, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the third quarter ended September 30, 2024 and provided a corporate update.
Celldex Therapeutics' Strong Cash Runway Supports Barzolvolimab's Path To Market
Celldex's primary revenue driver is Barzolvolimab, now in Phase 3 for CSU, targeting unmet needs in inflammatory diseases. Barzolvolimab has shown strong Phase 2 efficacy for CSU, though safety concerns may affect patient adherence. Celldex's solid cash position and long...
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
HAMPTON, N.J., Oct. 26, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive results from the Company's Phase 2 clinical trial of barzolvolimab in two of the most common forms of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and...
Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024
HAMPTON, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that 12 week results from the Company's Phase 2 clinical trial of barzolvolimab in two of the most common forms of chronic inducible urticaria (CIndU)—cold urticaria...
CLDX Stock Down Despite Upbeat Long-Term Data From Urticaria Study
Celldex stock falls due to safety concerns related to the treatment of urticaria patients with barzolvolimab in a phase II study, despite robust efficacy data.
Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024
- 71% of patients (150 mg Q4W) achieved complete response at Week 52 - - Rapid, profound and durable improvement in UAS7 as early as Week 1 with a deepening of response over 52 weeks - - Robust improvement across...
Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024
HAMPTON, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that an abstract describing 52 week results from the Company's Phase 2 clinical trial of barzolvolimab in patients with moderate to severe chronic spontaneous urticaria (CSU)...
Source: https://incomestatements.info
Category: Stock Reports